Psychiatry & Neurology Doctors in Swainsboro, GA Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Daniel F. Ward, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 125c Victory Dr, Swainsboro, GA 30401 Phone: 478-289-1100    Fax: 478-289-1190

Roy Thomas Harry, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 223 N Anderson Dr, Swainsboro, GA 30401 Phone: 478-289-2530    Fax: 478-289-2532

Robert Edward Shervette Iii, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 223 N Anderson Dr, Swainsboro, GA 30401 Phone: 478-289-2683    Fax: 478-289-2681

Dr. David Michael Bate, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 223 N Anderson Dr, Swainsboro, GA 30401 Phone: 478-289-2683    Fax: 478-289-2681

News Archive

Protein regulates movement of mitochondria in brain cells

Scientists have identified a protein in the brain that plays a key role in the function of mitochondria - the part of the cell that supplies energy, supports cellular activity, and potentially wards off threats from disease.The discovery, which was reported today in the Journal of Cell Biology, may shed new light on how the brain recovers from stroke.

Squabbling Democrats prepare to move ahead on health bills without GOP

The New York Times: "Democrats now say they see little chance of the minority's cooperation in approving any overhaul, and are increasingly focused on drawing support for a final plan from within their own ranks. Top Democrats said Tuesday that their go-it-alone view was being shaped by what they saw as Republicans' purposely strident tone against health care legislation during this month's Congressional recess, as well as remarks by leading Republicans that current proposals were flawed beyond repair."

Research progress with promising Alzheimer's drug Xanamem

Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer's disease and other major age-related neurodegenerative disorders, is pleased to announce that it has received ethics approval to initiate the third and final stage of the second Phase I trial of its lead Alzheimer's drug candidate, Xanamem™.

IUPUI professor earns CAREER award for improving machine learning technology

A computer science professor at Indiana University-Purdue University Indianapolis (IUPUI) has earned the prestigious CAREER Award from the National Science Foundation (NSF) to research ways to help computers actively adjust models and classify new data by enhancing machine learning technology.

Read more Medical News

› Verified 8 days ago